We have reported a novel, clean and efficient synthesis of new spiro[indene-2,2'-[1,3,5]oxathiazine derivatives 4 by a three-
component reaction. Simple procedure for product isolation, lack of problems connected with conventional solvent use, good yields
are the main features of this method. The products described in this article have two important biological active moieties therefore,
synthetic and biological applications of compounds 4 can be considered in the near future.
4. Experimental
All starting materials were purchased from Merck (Germany) and Fluka (Switzerland) and were used without further
purification. All products were identified with the following methods: Melting points: Electrothermal 9100 apparatus; Elemental
analyses for C, H, and N: Heraeus CHN–O–Rapid analyzer; Mass spectra: Finnigan-Matt 8430 mass spectrometer operating at an
1
ionization potential of 70 eV; H NMR and 13C NMR spectra: at 500 and 125 MHz, respextively, on a Bruker Advance DRX-500
MHz in CDCl3; IR Spectra: in KBr on a Shimadzu IR-460 spectrometer.
General procedure for the synthesis of spiro[indene-2,2'-[1,3,5]oxathiazine]-1,3-diones 4a-g: A solution of tetramethyl guanindine
(1 mmol) and isothiocyanate derivatives (3a-g) (1 mmol) in water (2 mL) were magnetically stirred for 5 min to obtained
intermediate 6. Then, ninhydrin (1 mmol) was added to reaction mixture and the solution was stirred for appropriate time at room
temperature. The reaction products were monitored using thin layer chromatography (TLC). After completion of the reaction, the
mixture was filtered, and the precipitate was washed with ether (4 mL) to afford the pure product 4a-g.
4'-((4-Chlorophenyl)imino)-6'-(dimethylamino)-4'H-spiro[indene-2,2'-[1,3,5]oxathiazine]-1,3-dione (4a, Table 2, entry a): Yield:
94%. Yellow powder; mp 126-128 °C. IR (KBr, cm-1): max 1171, 1241, 1374, 1496, 1533, 1723; 1H NMR (500 MHz, CDCl3): δ 3.59
(s, 6H, NMe2), 7.39 (d, 2H, 3J = 7.5 Hz, Ar), 7.64 (t, 2H, 3J = 7.5 Hz, Ar), 7.91 (d, 2H, 3J = 7.9 Hz, Ar), 8.04 (d, 2H, 3J = 7.9 Hz, Ar);
13C NMR (125 MHz, CDCl3): δ 44.0, 110.9, 127.4, 127.5, 130.1, 130.7, 130.9, 133.3, 135.7, 164.5, 167.6, 195.8; MS (EI, 70 eV): m/z
(%)= 399 (M+, 48), 354 (25), 255 (43), 191 (69), 144 (100), 111 (80), 77 (95); Anal. Calcd. for C19H14ClN3O3S: C, 57.07; H, 3.53; N,
10.51. Found: C, 57.01; H, 3.44; N, 10.87.
6'-(Dimethylamino)-4'-(p-tolylimino)-4'H-spiro[indene-2,2'-[1,3,5]oxathiazine]-1,3-dione (4b, Table 2, entry b): Yield: 85%.
1
Yellow powder; mp 131-133 °C. IR (KBr, cm-1): max 1170, 1257, 1367, 1461, 1529, 1723; H NMR (500 MHz, CDCl3): δ 2.49 (s,
3H, Me), 3.88 (s, 6H, NMe2), 7.10 (d, 2H, 3J = 7.6 Hz, Ar), 7.30 (t, 2H, 3J = 7.6 Hz, Ar), 7.40 (d, 2H, 3J = 7.8 Hz, Ar), 7.93 (d, 2H, 3J
= 7.8 Hz, Ar); 13C NMR (125 MHz, CDCl3): δ 22.2, 45.7, 110.9, 125.1, 126.1, 127.5, 129.2, 130.0, 130.3, 130.6. 162.5, 166.0, 195.2;
MS (EI, 70 eV): m/z (%) = 379 (M+, 66), 335 (46), 235 (59), 187 (96), 144 (80), 91 (88), 77 (100); Anal. Calcd. for C20H17N3O3S: C,
63.31; H, 4.52; N, 11.07. Found: C, 63.45; H, 4.39; N, 10.83.
Other data of compounds 4c-g are deposited in Supporting information.
Acknowledgement
We gratefully acknowledge financial support from the Research Council of Science and Research Branch, Islamic Azad
University.
References
[1] (a) J. Zhu, H. Bienayme, Multicomponent reactions, Wiley-VCH: Weinheim, Germany. (2006);
(b) A. Dömling, Recent developments in isocyanide based multicomponent reactions in applied chemistry, Chem. Rev. 106 (2006) 17-89;
(c) P. Lu, Y. Wang, Strategies for heterocyclic synthesis via cascade reactions based on ketenimines, Synlett (2010) 165-173;
(d) B. Ganem, Strategies for innovation in multicomponent reaction design, Acc. Chem. Res. 42 (2009) 463-472;
(e) D.J. Ramón, M. Yus, Asymmetric multicomponent reactions (AMCRs), Angew. Chem. Int. Ed. 44 (2005) 1602-1634.
[2] (a) R. Fringuelli, L. Milanese, F. Schiaffella, Role of 1, 4-benzothiazine derivatives in medicinal chemistry, Mini Rev. Med. Chem. 5
(2005) 1061-1073;
(b) H. Li, G.J Dryhurst, Irreversible inhibition of mitochondrial complex I by 7‐(2‐aminoethyl)‐3,4‐dihydro‐5‐hydroxy‐2H‐1,4‐
benzothiazine‐3‐carboxylic acid (DHBT‐1): a putative nigral endotoxin of relevance to parkinson's disease, Neurochem. 69 (1997)
1530-1541.
[3] C. Giordano, M. Ferraris, E. Barsuglia, Methods of combatting nematodes using certain derivatives of 1,3,5-oxathiazine, Montedison
Fibre SPA, U.S. Patent 4,035,496 (1977).
[4] (a) W.G. Brouwer, A.R. Bell, A.R. Blem, R.A. Davis, 3-Aryl-5,6-dihydro-1,4,2-oxathiazines and their oxides, U.S. Patent 4,569,690,
issued February 11 (1986);
(b) W.G. Brouwer, A.R. Bell, A.R. Blem, R.A. Davis, 3-Aryl-5,6-dihydro-1,4,2-oxathiazines and their oxides, U.S. Patent 4,675,044,
issued June 23 (1987)
(c) W.G. Brouwer, A.R. Bell, A.R. Blem, R.A. Davis, 3-Aryl-5,6-dihydro-1,4,2-oxathiazines and their oxides, Eur. Patent 0,104,940 A1
(1984).
[5] (a) J.F.E. Van Gestel, Antibacterial and antifouling oxathiazines and their oxides, U.S. Patent 5,712,275, issued January 27 (1998);
(b) J.F.E. Van Gestel, Antibacterial and antifouling oxathiazines and their oxides, U.S. Patent 5,922,113, issued July 13 (1999).